Superior Transduction of Mouse Hematopoietic Stem Cells with 10A1 and VSV-G Pseudotyped Retrovirus Vectors

Stephane Barrette, Janet Douglas, Donald Orlic, Stacie M. Anderson, Nancy E. Seidel, A. Dusty Miller, David M. Bodine

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The inefficient transduction of human hematopoietic stem cells (HSC) with amphotropic retroviral vectors has been an obstacle to gene therapy for hematopoietic diseases. We have previously reported low levels of amphotropic retrovirus receptor (Pit-2) mRNA and higher levels of gibbon ape leukemia virus (GALV) or 10A1 retrovirus receptor (Pit-1) mRNA in mouse and human HSC. The vesicular stomatitis virus (VSV-G) uses an abundant membrane phospholipid as a receptor. We hypothesized that transduction of HSC requires relatively high levels of retrovirus receptor molecules. Because mouse HSC can be efficiently transduced by ecotropic virus through the abundant ecotropic receptor, the mouse is an ideal model to compare receptor levels and transduction. We have developed a cotransduction assay where ecotropic retrovirus transduction is a positive internal control for downstream steps in retrovirus transduction. A comparison of mouse HSC transduction with amphotropic, 10A1, and VSV-G envelopes showed that the level of amphotropic and 10A1 receptor mRNA in HSC correlated with the frequency of transduction. Transduction with VSV-G vectors was similar to that with 10A1 vectors. We conclude that the level of retrovirus receptor on HSC is critical for HSC transduction and that GALV or VSV-G vectors would be better for human HSC transduction.

Original languageEnglish (US)
Pages (from-to)330-338
Number of pages9
JournalMolecular Therapy
Volume1
Issue number4
DOIs
StatePublished - Apr 2000
Externally publishedYes

Fingerprint

Retroviridae
Hematopoietic Stem Cells
Gibbon ape leukemia virus
Messenger RNA
Viruses
Vesicular Stomatitis
Genetic Therapy
Phospholipids
Membranes

Keywords

  • 10A1
  • Amphotropic
  • Hematopoietic stem cells
  • Murine
  • Pit-1
  • Pit-2
  • Retrovirus
  • Transduction

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Superior Transduction of Mouse Hematopoietic Stem Cells with 10A1 and VSV-G Pseudotyped Retrovirus Vectors. / Barrette, Stephane; Douglas, Janet; Orlic, Donald; Anderson, Stacie M.; Seidel, Nancy E.; Miller, A. Dusty; Bodine, David M.

In: Molecular Therapy, Vol. 1, No. 4, 04.2000, p. 330-338.

Research output: Contribution to journalArticle

Barrette, Stephane ; Douglas, Janet ; Orlic, Donald ; Anderson, Stacie M. ; Seidel, Nancy E. ; Miller, A. Dusty ; Bodine, David M. / Superior Transduction of Mouse Hematopoietic Stem Cells with 10A1 and VSV-G Pseudotyped Retrovirus Vectors. In: Molecular Therapy. 2000 ; Vol. 1, No. 4. pp. 330-338.
@article{530723d0d47340858d4ffd146f085639,
title = "Superior Transduction of Mouse Hematopoietic Stem Cells with 10A1 and VSV-G Pseudotyped Retrovirus Vectors",
abstract = "The inefficient transduction of human hematopoietic stem cells (HSC) with amphotropic retroviral vectors has been an obstacle to gene therapy for hematopoietic diseases. We have previously reported low levels of amphotropic retrovirus receptor (Pit-2) mRNA and higher levels of gibbon ape leukemia virus (GALV) or 10A1 retrovirus receptor (Pit-1) mRNA in mouse and human HSC. The vesicular stomatitis virus (VSV-G) uses an abundant membrane phospholipid as a receptor. We hypothesized that transduction of HSC requires relatively high levels of retrovirus receptor molecules. Because mouse HSC can be efficiently transduced by ecotropic virus through the abundant ecotropic receptor, the mouse is an ideal model to compare receptor levels and transduction. We have developed a cotransduction assay where ecotropic retrovirus transduction is a positive internal control for downstream steps in retrovirus transduction. A comparison of mouse HSC transduction with amphotropic, 10A1, and VSV-G envelopes showed that the level of amphotropic and 10A1 receptor mRNA in HSC correlated with the frequency of transduction. Transduction with VSV-G vectors was similar to that with 10A1 vectors. We conclude that the level of retrovirus receptor on HSC is critical for HSC transduction and that GALV or VSV-G vectors would be better for human HSC transduction.",
keywords = "10A1, Amphotropic, Hematopoietic stem cells, Murine, Pit-1, Pit-2, Retrovirus, Transduction",
author = "Stephane Barrette and Janet Douglas and Donald Orlic and Anderson, {Stacie M.} and Seidel, {Nancy E.} and Miller, {A. Dusty} and Bodine, {David M.}",
year = "2000",
month = "4",
doi = "10.1006/mthe.2000.0052",
language = "English (US)",
volume = "1",
pages = "330--338",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Superior Transduction of Mouse Hematopoietic Stem Cells with 10A1 and VSV-G Pseudotyped Retrovirus Vectors

AU - Barrette, Stephane

AU - Douglas, Janet

AU - Orlic, Donald

AU - Anderson, Stacie M.

AU - Seidel, Nancy E.

AU - Miller, A. Dusty

AU - Bodine, David M.

PY - 2000/4

Y1 - 2000/4

N2 - The inefficient transduction of human hematopoietic stem cells (HSC) with amphotropic retroviral vectors has been an obstacle to gene therapy for hematopoietic diseases. We have previously reported low levels of amphotropic retrovirus receptor (Pit-2) mRNA and higher levels of gibbon ape leukemia virus (GALV) or 10A1 retrovirus receptor (Pit-1) mRNA in mouse and human HSC. The vesicular stomatitis virus (VSV-G) uses an abundant membrane phospholipid as a receptor. We hypothesized that transduction of HSC requires relatively high levels of retrovirus receptor molecules. Because mouse HSC can be efficiently transduced by ecotropic virus through the abundant ecotropic receptor, the mouse is an ideal model to compare receptor levels and transduction. We have developed a cotransduction assay where ecotropic retrovirus transduction is a positive internal control for downstream steps in retrovirus transduction. A comparison of mouse HSC transduction with amphotropic, 10A1, and VSV-G envelopes showed that the level of amphotropic and 10A1 receptor mRNA in HSC correlated with the frequency of transduction. Transduction with VSV-G vectors was similar to that with 10A1 vectors. We conclude that the level of retrovirus receptor on HSC is critical for HSC transduction and that GALV or VSV-G vectors would be better for human HSC transduction.

AB - The inefficient transduction of human hematopoietic stem cells (HSC) with amphotropic retroviral vectors has been an obstacle to gene therapy for hematopoietic diseases. We have previously reported low levels of amphotropic retrovirus receptor (Pit-2) mRNA and higher levels of gibbon ape leukemia virus (GALV) or 10A1 retrovirus receptor (Pit-1) mRNA in mouse and human HSC. The vesicular stomatitis virus (VSV-G) uses an abundant membrane phospholipid as a receptor. We hypothesized that transduction of HSC requires relatively high levels of retrovirus receptor molecules. Because mouse HSC can be efficiently transduced by ecotropic virus through the abundant ecotropic receptor, the mouse is an ideal model to compare receptor levels and transduction. We have developed a cotransduction assay where ecotropic retrovirus transduction is a positive internal control for downstream steps in retrovirus transduction. A comparison of mouse HSC transduction with amphotropic, 10A1, and VSV-G envelopes showed that the level of amphotropic and 10A1 receptor mRNA in HSC correlated with the frequency of transduction. Transduction with VSV-G vectors was similar to that with 10A1 vectors. We conclude that the level of retrovirus receptor on HSC is critical for HSC transduction and that GALV or VSV-G vectors would be better for human HSC transduction.

KW - 10A1

KW - Amphotropic

KW - Hematopoietic stem cells

KW - Murine

KW - Pit-1

KW - Pit-2

KW - Retrovirus

KW - Transduction

UR - http://www.scopus.com/inward/record.url?scp=0034171107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034171107&partnerID=8YFLogxK

U2 - 10.1006/mthe.2000.0052

DO - 10.1006/mthe.2000.0052

M3 - Article

C2 - 10933951

AN - SCOPUS:0034171107

VL - 1

SP - 330

EP - 338

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 4

ER -